Loading the security overview…
Where the tokens are
| Quarter | Reported | EPS | EPS vs year ago | Revenue | Revenue vs year ago | Consensus EPS |
|---|---|---|---|---|---|---|
| Q2 FY26ended Jun 30, 2026 | Aug 3, 2026 | $4.31 | +8.0% | $3.33B | +12.5% | $4.74 |
| Q1 FY26ended Mar 31, 2026 | May 4, 2026 | $4.02 | +61.4% | $2.99B | +7.8% | $4.23 |
| Q4 FY25ended Dec 31, 2025 | — | $4.65 | +28.1% | $3.19B | +9.5% | — |
| Q3 FY25ended Sep 30, 2025 | — | $4.20 | +4.7% | $3.08B | +11.0% | — |
| Q2 FY25ended Jun 30, 2025 | — | $3.99 | — | $2.96B | +12.1% | — |
| Q1 FY25ended Mar 31, 2025 | — | $2.49 | −40.9% | $2.77B | +3.0% | — |
| Q4 FY24ended Dec 31, 2024 | — | $3.63 | −2.4% | $2.91B | +15.7% | — |
| Q3 FY24ended Sep 30, 2024 | — | $4.01 | +1.0% | $2.77B | +11.6% |
Growth compares each quarter with the same fiscal quarter a year earlier, and is left blank where that quarter is missing or its figure was zero or a loss. Consensus is the estimate published before each report. It usually refers to adjusted EPS, so it is shown beside the GAAP figure rather than subtracted from it: the difference would not be a beat or a miss.
Figures describe Vertex Pharmaceuticals shares, not any token. As of Aug 3, 2026, from Massive's standardised financials and the earnings calendar.
| — |
| Q2 FY24ended Jun 30, 2024 | — | −$13.92 | — | $2.65B | — | — |
| Q1 FY24ended Mar 31, 2024 | — | $4.21 | — | $2.69B | — | — |
| Q4 FY23ended Dec 31, 2023 | — | $3.72 | — | $2.52B | — | — |
| Q3 FY23ended Sep 30, 2023 | — | $3.97 | — | $2.48B | — | — |